 Connection
Atsushi Oba to Biomarkers, Tumor
This is a "connection" page, showing publications Atsushi Oba has written about Biomarkers, Tumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.660 |
|
|
|
-
Oba A, Ban D, Kirimura S, Akahoshi K, Mitsunori Y, Matsumura S, Ochiai T, Kudo A, Tanaka S, Minoru T. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2016 Aug; 23(8):480-8.
Score: 0.291
-
Omiya K, Oba A, Sugiura K, Maekawa A, Mie T, Kobayashi K, Ono Y, Sasaki T, Ozaka M, Sasahira N, Ito H, Inoue Y, Takahashi Y. Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy. Ann Surg Oncol. 2025 Aug; 32(8):5411-5420.
Score: 0.135
-
Akahoshi K, Ban D, Kuboki R, Oba A, Ono H, Mitsunori Y, Kudo A, Tanaka S, Tanabe M. Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients. J Gastroenterol Hepatol. 2019 Jun; 34(6):1108-1115.
Score: 0.086
-
Maekawa A, Oba A, Mie T, Sawa Y, Baba H, Kobayashi K, Ono Y, Sato T, Ito H, Sasaki T, Ozaka M, Sasahira N, Takamatsu M, Ban D, Inoue Y, Takahashi Y. Exploring the role of CA 19-9 dynamics in pancreatic cancer multidisciplinary treatment: Proposal of the PANC classification. Surgery. 2025 Dec; 188:109783.
Score: 0.035
-
Hirose Y, Oba A, Takamatsu M, Hamada T, Takeda T, Suzuki T, Maekawa A, Kitano Y, Sato S, Kobayashi K, Omiya K, Ono Y, Sato T, Ito H, Sasaki T, Ozaka M, Takeuchi K, Sasahira N, Inoue Y, Wakai T, Takahashi Y. Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. Pancreatology. 2024 Nov; 24(7):1021-1030.
Score: 0.032
-
Kobayashi K, Ono Y, Kitano Y, Oba A, Sato T, Ito H, Mise Y, Shinozaki E, Inoue Y, Yamaguchi K, Saiura A, Takahashi Y. Prognostic Impact of Tumor Markers (CEA and CA19-9) on Patients with Resectable Colorectal Liver Metastases Stratified by Tumor Number and Size: Potentially Valuable Biologic Markers for Preoperative Treatment. Ann Surg Oncol. 2023 Nov; 30(12):7338-7347.
Score: 0.030
-
Omiya K, Oba A, Inoue Y, Kobayashi K, Wu YHA, Ono Y, Sato T, Sasaki T, Ozaka M, Sasahira N, Ito H, Saiura A, Takahashi Y. Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. Ann Surg. 2023 06 01; 277(6):e1278-e1283.
Score: 0.027
-
Ushida Y, Inoue Y, Ito H, Oba A, Mise Y, Ono Y, Sato T, Saiura A, Takahashi Y. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. Pancreatology. 2021 Jan; 21(1):130-137.
Score: 0.025
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|